TiGenix News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.07.18	Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period (GlobeNewswire)
23.07.18	TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
06.07.18	Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid (GlobeNewswire)
02.07.18	TiGenix: Transparency Information (GlobeNewswire)
27.06.18	TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
22.06.18	TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
19.06.18	TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
14.06.18	Transparency notification pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
13.06.18	TiGenix announces a change in its Board of Directors and its Management Team (GlobeNewswire)
06.06.18	Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period (GlobeNewswire)
28.05.18	TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
14.05.18	TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
08.05.18	TiGenix: CONVENING NOTICE TO THE ANNUAL SHAREHOLDERS' MEETING TO BE HELD ON 7 JUNE 2018 (GlobeNewswire)
27.04.18	TiGenix: Publication of prospectus and response memorandum for Takeda takeover bid commencing on April 30, 2018 (GlobeNewswire)
26.04.18	TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
13.04.18	TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
12.04.18	TiGenix reports 2017 full year results (GlobeNewswire)
10.04.18	TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
30.03.18	TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
23.03.18	TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval to treat complex perianal fistulas in Crohn's disease in Europe (GlobeNewswire)
06.02.18	TiGenix: Transparency Information (GlobeNewswire)
31.01.18	TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
26.01.18	TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
19.01.18	TiGenix: Transparency Information (GlobeNewswire)
18.01.18	TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
16.01.18	TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
15.01.18	TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 (GlobeNewswire)
12.01.18	Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
11.01.18	TiGenix: Transparency Information (GlobeNewswire)
05.01.18	Takeda announces its intention to acquire TiGenix (GlobeNewswire)
03.01.18	Transparency notification pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
20.12.17	TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform (GlobeNewswire)
15.12.17	Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn's disease (GlobeNewswire)
15.12.17	Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae (GlobeNewswire)
24.11.17	JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix (GlobeNewswire)
16.11.17	TiGenix announces approval of trade name for lead development candidate Cx601 in Europe (GlobeNewswire)
06.11.17	TiGenix announces partial conversion of bonds (GlobeNewswire)
02.11.17	TiGenix strengthens European IP protection around lead development program Cx601 (GlobeNewswire)
31.10.17	TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure (GlobeNewswire)
23.10.17	TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601 (GlobeNewswire)
05.10.17	TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting (GlobeNewswire)
02.10.17	TiGenix to host Analyst and Investor Event in New York City (GlobeNewswire)
28.09.17	TiGenix to participate and present at key investor and business development meetings (GlobeNewswire)
19.09.17	TiGenix Business and Financial Update for the First Half 2017 (GlobeNewswire)
12.09.17	TiGenix strengthens US operations with senior appointments (GlobeNewswire)
05.09.17	TiGenix obtains commercial production license for expanded manufacturing facility (GlobeNewswire)
20.12.16	Takeda makes €10 million equity investment in TiGenix (GlobeNewswire)
26.10.16	TiGenix provides update on proposed initial public offering in the United States (GlobeNewswire)
26.10.16	TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
17.10.16	TiGenix Announces Orphan Drug Designation (ODD) for Cx601 in Switzerland (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’293.50	1.97 %	K V
ABB	50.04	1.13 %	K V
Holcim	89.00	1.04 %	K V
Roche Hldg G	266.60	0.83 %	K V
UBS Group	29.61	0.58 %	K V
Givaudan	3’884.00	-0.49 %	K V
Zurich Insur Gr	547.20	-0.83 %	K V
Geberit	508.20	-1.05 %	K V
Sonova Hldg	294.80	-1.07 %	K V
Logitech Intl	78.84	-1.30 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu TiGenix S.A.

Aktien Top/Flop

Meistgelesene Nachrichten